The official implementations of our BIBM'24 paper: Focus on Focus: Focus-oriented Representation Learning and Multi-view Cross-modal Alignment for Glioma Grading ...

The FDA has accepted and granted priority review for the new drug application for vorasidenib for the treatment of IDH-mutant diffuse glioma, with a PDUFA action date set for August 20, 2024. The FDA ...

However, the relationship between GRN and GBM remains unclear. We evaluated the role of GRN in GBM through The Cancer Genome Atlas (TCGA) database Methods: First, we assessed the relationship between ...

However, the precise underlying molecular mechanisms remain largely unknown. Data on gliomas in The Cancer Genome Atlas lack normal control samples; to overcome this limitation, we combined 665 The ...

A glioma that looks relatively unaggressive under a microscope may still have a lethal potential. That is a key finding of research recently published by the Cancer Genome Atlas Research Network ...

We performed genomewide analyses of 293 lower-grade gliomas from adults, incorporating exome sequence, DNA copy number, DNA methylation, messenger RNA expression, microRNA expression, and targeted ...

we applied a loss-of-function approach to identify miR-10b targets and explore its function in glioma growth in vitro and in vivo. These experiments, along with the analysis of The Cancer Genome Atlas ...